1 / 16

A. MTRR A 66G, AG vs. AA

kiona-harding
Télécharger la présentation

A. MTRR A 66G, AG vs. AA

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Online Supplementary Figure 2. Forest plots of significant odds ratios (ORs) of childhood acute lymphoblastic leukemia associated with polymorphic variants. Boxes denote allelic OR point estimates, their areas being proportional to the inverse variance weight of the estimate. Horizontal lines represent 95% confidence intervals. The diamond (and broken line) represents the summary ORs computed under a fixed effects model, with 95% confidence interval given by its width. The unbroken vertical line is at the null value (OR=1.0). (A) MTRR A66G, AG vs. AA; (B) MTRR A66G, GG vs. AA; (C) MTRR A66G, GG+AG vs. AA; (D) SHMT1 C1420T, CT vs. CC; (E) RFC1 G80A, GA vs. GG; (F) RFC1 G80A, AA vs. GG; (G) RFC1 G80A, GA+AA vs. GG; (H) NQO1 C609T, CT+TT vs. CC; (I) GSTM1, null vs. present; (J) CYP1A1 T6235C, TC vs. TT; (K) CYP1A1 T6235C, CT+CC vs. TT; (L) CYP2E1*5B, heterozygous; (M) CYP2E1*5B, carrier status; (N) XRCC1 G28152A, GA vs. GG; (O) XRCC1 G28152A, GA+AA vs. GG;

  2. Odds ratio Study (95% CI) Petra G et al 0.83 (0.42,1.65) de Jonge et al 0.82 (0.55,1.21) Gast et al 0.71 (0.52,0.99) Overall (95% CI) 0.76 (0.60,0.96) Phet=0.85 .4 1 2 A. MTRR A66G, AG vs. AA

  3. Odds ratio (95% CI) Study Petra G et al 0.71 (0.32,1.56) de Jonge et al 0.74 (0.48,1.14) Gast et al 0.63 (0.43,0.90) Overall (95% CI) 0.67 (0.52,0.88) Phet=0.84 .3 1 1.7 B. MTRR A66G, GG vs. AA

  4. Odds ratio Study (95% CI) Petra G et al 0.79 (0.41,1.51) de Jonge et al 0.79 (0.55,1.13) Gast et al 0.68 (0.50,0.93) Overall (95% CI) 0.73 (0.59,0.91) Phet=0.82 .4 1 1.7 C. MTRR A66G, GG+AG vs. AA

  5. Odds ratio (95% CI) Study de Jonge et al 0.72 (0.52,1.00) Gast et al 0.84 (0.65,1.10) Overall (95% CI) 0.79 (0.65,0.98) Phet=0.46 .5 1 1.2 D. SHMT1 C1420T, CT vs. CC

  6. Odds ratio Study (95% CI) de Jonge et al 1.34 (0.94,1.91) Gast et al 1.40 (1.05,1.86) Overall (95% CI) 1.37 (1.10,1.72) Phet=0.87 .8 1 2 E. RFC1 G80A, GA vs. GG

  7. Odds ratio Study (95% CI) de Jonge et al 2.06 (1.31,3.25) Gast et al 1.04 (0.72,1.51) Overall (95% CI) 1.36 (1.02,1.81) Phet=0.02 .6 1 4 F. RFC1 G80A, AA vs. GG

  8. Odds ratio Study (95% CI) de Jonge et al 1.50 (1.08,2.09) Gast et al 1.29 (0.98,1.70) Overall (95% CI) 1.37 (1.11,1.69) .8 1 2.5 Phet=0.49 G. RFC1 G80, GA+AA vs. GG

  9. Odds ratio Study (95% CI) Wiemels et al 1.84 (1.03,3.26) Eguchi Ishimae et al 1.20 (0.69,2.07) Clavel et al 1.07 (0.65,1.76) Lanciotti et al 1.07 (0.68,1.70) Kracht et al 0.98 (0.62,1.57) Krajinovic et al 1.49 (1.02,2.19) Overall (95% CI) 1.24 (1.02,1.50) Phet=0.49 .6 1 3.5 H. NQO1C609T, CT+TT vs. CC

  10. Odds ratio Study (95% CI) Saadat I et al, 2.63 (1.18,5.86) Chen et al 1.84 (0.87,3.89) Alves et al 2.22 (1.07,4.58) Davies S M et al 1.43 (0.68,2.99) Joseph et al 2.10 (1.21,3.67) Sayitoglu et al 1.56 (0.94,2.58) Pakakasama et al 1.66 (1.03,2.66) Clavel et al 1.07 (0.66,1.72) Balta et al 1.03 (0.66,1.61) Canalle et al 0.88 (0.56,1.39) Krajinovic M et al 1.76 (1.20,2.58) Barnette et al 0.82 (0.51,1.29) Chen et al 1.07 (0.71,1.61) Pigullo et al 0.82 (0.61,1.10) Davies S M et al 1.00 (0.79,1.26) Overall (95% CI) 1.16 (1.04,1.30) Phet<0.01 .45 1 6 I. GSTM1, null vs. present

  11. Odds ratio Study (95% CI) Joseph et al 2.58 (1.41,4.72) Sayitoglu 1.74 (1.00,3.05) Krajinovic et al 1.87 (1.10,3.17) Balta G et al 1.37 (0.78,2.40) Lee et al 1.25 (0.72,2.16) Clavel J et al 0.75 (0.42,1.35) Canalle R et al 0.96 (0.59,1.58) Overall (95% CI) 1.38 (1.12,1.70) Phet=0.06 .35 1 5 J. CYP1A1 T6235C, TC vs. TT

  12. Odds ratio Study (95% CI) Joseph et al 2.88 (1.62,5.13) Krajinovic et al 1.82 (1.08,3.05) Sayitoglu et al 1.58 (0.92,2.71) Balta G et al 1.17 (0.68,2.02) Clavel J et al 0.82 (0.46,1.46) Lee et al 1.06 (0.63,1.78) Canalle R et al 1.09 (0.68,1.75) Overall (95% CI) 1.36 (1.11,1.66) Phet=0.04 .4 1 5.5 K. CYP1A1 T6235C, CT+CC vs. TT

  13. Odds ratio Study (95% CI) Sayitoglu et al 3.47 (1.31,9.18) Krajinovic et al 2.85 (1.21,6.73) Ulusoy et al 1.91 (0.76,4.80) Canalle R et al 1.21 (0.60,2.46) Overall (95% CI) 2.03 (1.34,3.06) Phet=0.28 .5 1 10 L. CYP2E1 *5B, heterozygous

  14. Odds ratio (95% CI) Study Sayitoglu et al 3.47 (1.31,9.18) Krajinovic et al 2.85 (1.21,6.73) Ulusoy et al 1.91 (0.76,4.80) Canalle R et al 1.16 (0.58,2.34) Overall (95% CI) 1.99 (1.32,3.00) Phet=0.24 .5 1 10 M. CYP2E1 *5B, carrier status

  15. Odds ratio Study (95% CI) Batar B et al 1.00 (0.48,2.07) Joseph et al 1.90 (1.08,3.35) Pakakasama et al 2.17 (1.36,3.45) Overall (95% CI) 1.78 (1.30,2.46) Phet=0.20 .4 1 4 N. XRCC1 G28152A, GA vs. GG

  16. Odds ratio Study (95% CI) Batar B et al 0.90 (0.45,1.80) Joseph et al 2.01 (1.19,3.40) Pakakasama et al 2.18 (1.39,3.42) Overall (95% CI) 1.78 (1.32,2.42) Phet=0.10 .4 1 4 O. XRCC1 G28152A, GA+AA vs. GG

More Related